TCR-like mAbs treatment reduces BLCL numbers, with E1 conferring delayed weight loss and enhanced survival. (A) Representative hCD45 vs mouse CD45 (mCD45) dot plots for each treatment group, with days post-EBV BLCL engraftment indicated. (B) Compiled percentages of hCD45 cells detected in the livers, spleens, and bone marrow (BM) from terminal analysis of EBV BLCL engrafted NSG mice. Results were expressed as mean ± SD. *P < .05 (unpaired Student t test). (C) Mice were monitored for changes in weight and were killed when values fell beneath 20% of original weight. Data are representative of 2 independent experiments. (D) Kaplan-Meier analysis comparing survival of mice between each treatment group. P value represents log-rank Mantel-Cox test result.